Stifel maintains Buy on Bicara stock with $47 target
Stifel analysts reiterated a Buy rating on Bicara Therapeutics Inc (NASDAQ:BCAX), maintaining a $47.00 price target. Trading ...
Strong Growth Potential Could Lift These 2 AI-Related Stocks Higher, Says Stifel
The race for AI supremacy has taken an unexpected twist as Chinese AI startup DeepSeek’s latest AI model, which is both ...
Diversified Expands Asset Base, Density, and Commodity Mix with Acquisition of Liquids Rich Maverick Natural Resources
Financial and Strategic Accretive Acquisition Provides Opportunity for 95% Increase in Revenue, Enhanced Margins, Expense Synergies, and 55% Increase in Free Cash Flow ...
Portillo’s upgraded to Buy from Hold at Stifel
Stifel analyst Chris O’Cull upgraded Portillo’s (PTLO) to Buy from Hold with a price target of $16, up from $13. The firm previously downgraded ...